Summit Tx Capital, L.P. Immatics N.V. Transaction History
Summit Tx Capital, L.P.
- $2.42 Trillion
- Q3 2025
A detailed history of Summit Tx Capital, L.P. transactions in Immatics N.V. stock. As of the latest transaction made, Summit Tx Capital, L.P. holds 44,466 shares of IMTX stock, worth $453,553. This represents 0.02% of its overall portfolio holdings.
Number of Shares
44,466
Previous 60,920
27.01%
Holding current value
$453,553
Previous $328 Million
15.59%
% of portfolio
0.02%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding IMTX
# of Institutions
67Shares Held
93MCall Options Held
53.8KPut Options Held
0-
T. Rowe Price Investment Management, Inc. Baltimore, MD19.4MShares$198 Million0.1% of portfolio
-
Baker Bros. Advisors LP New York, NY12.1MShares$123 Million0.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY12MShares$123 Million3.08% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$95.7 Million0.18% of portfolio
-
Rtw Investments, LP New York, NY8.82MShares$89.9 Million1.0% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $778M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...